Evaluation of Intervention Strategy of Thalassemia for Couples of Childbearing Ages in Centre of Southern China
Overview
Biotechnology
Pathology
Authors
Affiliations
Background: To describe the free intervention strategy of thalassemia for childbearing couples in Guangzhou.
Methods: Routine hematology examinations were conducted for 137,222 couples. Among them, 37,501 couples who had mean corpuscular volume (MCV) <82 fL or mean corpuscular hemoglobin <27 pg were elected for Hb analysis and the deletions of four common α-thalassemia mutation. Reverse dot blot for common nondeletional α-thalassemia and β-thalassemia was selectively used. Three thousand twenty-two couples randomly selected were offered all those tests as a control group. Sanger sequencing, multiplex ligation-dependent probe amplification and next-generation sequencing were used for rare thalassemia. High-risk couples were offered prenatal diagnosis at 10-13 weeks' gestation based on informed consent.
Results: The carrier rates of α-, β-, and αβ-thalassemia and δβ thalassemia/deletional HPFH were 7.7%, 3.02%, 0.5% and 0.059% respectively. Of them, 1.37% were identified as at-risk couples and 345 couples terminated the pregnancy. No severe α- and β-thalassemia births were observed. In the control group, two β- thalassemia carriers and one case with -α /αα were misdiagnosed, but all at-risk couples were found, and we could save 1,523,774 ¥ using our strategy. The cut-off points of 73.46 fL and 23.25 pg would be useful to find -α /α thalassemia.
Conclusion: The intervention strategy was cost-effective and offered reference in population thalassemia screening.
Li D, Liang L, Meng D, He S Front Genet. 2024; 15:1416047.
PMID: 38894721 PMC: 11183328. DOI: 10.3389/fgene.2024.1416047.
Ont Health Technol Assess Ser. 2023; 23(4):1-398.
PMID: 37637488 PMC: 10453298.
Utilization of multiple genetic methods for prenatal diagnosis of rare thalassemia variants.
Jiang F, Zhou J, Zuo L, Tang X, Li J, Li F Front Genet. 2023; 14:1208102.
PMID: 37529778 PMC: 10387553. DOI: 10.3389/fgene.2023.1208102.
Jiang F, Zuo L, Li J, Chen G, Tang X, Zhou J J Clin Lab Anal. 2021; 35(10):e23990.
PMID: 34492731 PMC: 8529143. DOI: 10.1002/jcla.23990.